This suggests that SILD affects circulating myeloid subpopulations in diabetes by lowering CD11b+GR1+ levels to those of non-diabetic mice and increasing the relative percentage of CD11b+GR1- cells. This evidence concerns the gene ITGAM and diabetes mellitus.